The collaboration between Moderna and Merck has generated exciting results in the fight against skin cancer, particularly in patients with melanoma. In a recent mid-stage study involving 157 patients, the combination of their cancer vaccine with the widely used therapy Keytruda demonstrated significant improvements in survival rates and long-term efficacy.
Detailed data from the trial revealed that after two and a half years, melanoma patients receiving the cancer vaccine combination exhibited an impressive overall survival rate of 96%, surpassing the 90.2% rate observed in patients treated with Keytruda alone. Furthermore, approximately 75% of patients on the vaccine combination experienced recurrence-free survival, a notable increase compared to the 55.6% in the Keytruda-only group.
The study's findings not only underscore the vaccine's efficacy but also highlight its durability in managing melanoma. A previous report in December had already shown a 49% reduction in the risk of recurrence or death among patients on the vaccine combination versus those on Keytruda alone, with a median follow-up period of nearly three years.
The partnership between Merck and Moderna, which dates back to 2016, represents a promising example of utilizing cutting-edge mRNA vaccine technology to harness the immune system for targeted cancer treatment. The companies are currently progressing with a late-stage study to further investigate the potential of their vaccine and Keytruda combination, offering hope for better outcomes in melanoma patients moving forward.